Lv4
496 积分 2024-05-08 加入
什么时候才能不上班
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4小时前
待确认
Next steps in regulatory T cells: Biology and clinical application
5天前
已完结
Functional and Metabolic Heterogeneity of Dendritic Cells in Self‐Tolerance and Autoimmunity
7天前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
8天前
已完结
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
12天前
已完结
Microwave Ablation for Inoperable Stage I Non–Small Cell Lung Cancer in Patients Aged ≥70 Years: A Prospective, Single-Center Study
14天前
已完结
Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022
21天前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
25天前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
25天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
25天前
已完结
皖公网安备34019202002308
